ZYVOX May Lead to Shorter Hospital Stays

Article

TORONTO - Data recently presented during the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Toronto, Canada show that ZYVOX (linezolid injection, tablets and for oral suspension) may help some patients with certain difficult-to-treat infections be discharged from hospitals sooner. ZYVOX, according to its manufacturer Pharmacia, is associated with a significantly higher rate of hospital discharge in the first week of therapy among patients with complicated skin and soft tissue infections. For more information visit www.pharmacia.com.

Related Videos
Jill Holdsworth, MS, CIC, FAPIC, CRCST, NREMT, CHL
Jill Holdsworth, MS, CIC, FAPIC, CRCSR, NREMT, CHL, and Katie Belski, BSHCA, CRCST, CHL, CIS
Baby visiting a pediatric facility  (Adobe Stock 448959249 by Rawpixel.com)
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Picture at AORN’s International Surgical Conference & Expo 2024
Infection Control Today and Contagion are collaborating for Rare Disease Month.
Related Content